Literature DB >> 11971123

MRI in the diagnosis and management of multiple sclerosis.

Douglas L Arnold1, P M Matthews.   

Abstract

MRI techniques, including conventional T(2)-weighted and gadolinium (Gd)-enhanced T(1)-weighted images, have provided important insights into the pathophysiology of MS. Although the correlation of MRI measures with clinical disability and outcome continues to be investigated, MRI measures are routinely used both in clinical practice and in MS research. In addition to its use as a diagnostic tool, MRI is used as a surrogate marker to monitor disease progression and response to therapy. A variety of MRI measures are used in drug development studies and have aided our understanding of the potential benefits and possible mechanisms of action of drug therapies. Advances in MRI techniques may further elucidate the pathology of MS, thus providing opportunities for new treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971123     DOI: 10.1212/wnl.58.8_suppl_4.s23

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 2.  Evidence from biomarkers and surrogate endpoints.

Authors:  Andrew Feigin
Journal:  NeuroRx       Date:  2004-07

3.  Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths.

Authors:  B Benedetti; D J Rigotti; S Liu; M Filippi; R I Grossman; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

4.  Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.

Authors:  Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2018-01-11       Impact factor: 4.849

5.  Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?

Authors:  J Pakpoor; D Saylor; I Izbudak; L Liu; E M Mowry; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-06       Impact factor: 3.825

Review 6.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Peripheral third cranial nerve enhancement in multiple sclerosis.

Authors:  M Tariq Bhatti; Ilona M Schmalfuss; Lorna S Williams; Ronald G Quisling
Journal:  AJNR Am J Neuroradiol       Date:  2003-08       Impact factor: 3.825

Review 8.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

9.  High b-value q-space diffusion-weighted MRI of the human cervical spinal cord in vivo: feasibility and application to multiple sclerosis.

Authors:  Jonathan A D Farrell; Seth A Smith; Eliza M Gordon-Lipkin; Daniel S Reich; Peter A Calabresi; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-05       Impact factor: 4.668

Review 10.  Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Paul L McCormack; Lesley J Scott
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.